Graduate School, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China.
Graduate School, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Biomark Med. 2024;18(8):419-431. doi: 10.2217/bmm-2024-0087. Epub 2024 May 29.
To investigate the diagnostic potential of the miR-200 family for early detection in non-small cell lung cancer (NSCLC). A systematic search was conducted of PubMed, Embase and Web of Science databases to identify studies of the miR-200 family in NSCLC. Sixteen studies meeting the inclusion criteria were included in the analysis with a total of 20 cohorts. The combined sensitivity and specificity reached 73% and 85%, with an area under the curve of 0.83. Notably, miR-200b introduced heterogeneity. Subgroup analysis highlighted miR-200a and miR-141 as more sensitive, while blood-derived miRNAs showed slightly lower accuracy. The miR-200 family, predominantly assessed in blood, exhibits significant diagnostic potential for NSCLC, especially in distinguishing it from benign diseases.
为了探究 miR-200 家族在非小细胞肺癌（NSCLC）早期诊断中的应用潜力。我们系统地检索了 PubMed、Embase 和 Web of Science 数据库，以确定 miR-200 家族在 NSCLC 中的研究。共有 16 项符合纳入标准的研究被纳入分析，共计 20 个队列。合并的敏感性和特异性分别达到 73%和 85%，曲线下面积为 0.83。值得注意的是，miR-200b 引入了异质性。亚组分析突出了 miR-200a 和 miR-141 具有更高的敏感性，而血液衍生的 miRNA 显示出稍低的准确性。miR-200 家族主要在血液中进行评估，对 NSCLC 具有显著的诊断潜力，特别是在与良性疾病区分方面。
